Skip to content

Study · Randomized controlled trial · n = 78 · 2002

4 results

Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer.

du BA, Meier W, Lück HJ, Emon G, Moebus V, Schroeder W, Costa S, Bauknecht T, Olbricht S, Jackisch C, Richter B, Wagner U

Annals of oncology : official journal of the European Society for Medical Oncology1 Feb 2002Cited by 38 (Europe PMC)

PMID11886002 (opens in a new tab)DOI10.1093/annonc/mdf038 (opens in a new tab)PepBankPUB-11886002
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with refractory ovarian cancer, median survival was 30 weeks with leuprorelin and 36 weeks with treosulfan.

    In plain wordsIn refractory ovarian cancer, median survival was 30 weeks with leuprorelin versus 36 weeks with treosulfan.

    Peptide
    Leuprolide
    Outcome
    DecreaseMedian survival
    Study

    n = 78

    Comparator
    Treosulfan
    Outcome group
    Mortality · Cancer
    Studied dose
    3.75 mg every 4 weeks · subcutaneous or intramuscularAs given in this study (human).

    Measurements

    Median survival
    30 weeks
    leuprorelin
    Median survival
    36 weeks
    treosulfan

    Source sentences

    Summary
    The median survival time was 36 and 30 weeks in the treosulfan and leuprorelin arms, respectively.
    3 context sentences
    Summary · context
    Patients with ovarian cancer progressing during platinum-paclitaxel containing first-line therapy or experiencing relapse within 6 months were eligible.
    Summary · context
    Treatment consisted of either treosulfan 7 g/m5 infused over 30 min or leuprorelin 3.75 mg injected subcutaneously or intramuscularly. Both regimens were repeated every 4 weeks.
    Title · context
    a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer
  2. 02HumanNon-randomized trialSafety outcome

    In patients with refractory ovarian cancer, leuprorelin and treosulfan were both well tolerated.

    In plain wordsIn patients with refractory ovarian cancer, both leuprorelin and treosulfan were well tolerated.

    Peptide
    Leuprolide
    Outcome
    Not applicableTreatment tolerability
    Study

    n = 78

    Outcome group
    Adverse events · Whole body
    Studied dose
    3.75 mg every 4 weeks · subcutaneous or intramuscularAs given in this study (human).

    Source sentences

    Summary
    Overall, both treatment arms were well tolerated.
    2 context sentences
    Summary · context
    Patients with ovarian cancer progressing during platinum-paclitaxel containing first-line therapy or experiencing relapse within 6 months were eligible.
    Summary · context
    Treatment consisted of either treosulfan 7 g/m5 infused over 30 min or leuprorelin 3.75 mg injected subcutaneously or intramuscularly. Both regimens were repeated every 4 weeks.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with refractory ovarian cancer, no objective responses were observed with leuprorelin or treosulfan.

    In plain wordsIn patients with refractory ovarian cancer, no objective responses were observed with leuprorelin or treosulfan.

    Peptide
    Leuprolide
    Outcome
    Not applicableObjective response
    Study

    n = 78

    Outcome group
    Tumor growth · Cancer
    Studied dose
    3.75 mg every 4 weeks · subcutaneous or intramuscularAs given in this study (human).

    Source sentences

    Summary
    No objective responses were observed.
    2 context sentences
    Summary · context
    Patients with ovarian cancer progressing during platinum-paclitaxel containing first-line therapy or experiencing relapse within 6 months were eligible.
    Summary · context
    Treatment consisted of either treosulfan 7 g/m5 infused over 30 min or leuprorelin 3.75 mg injected subcutaneously or intramuscularly. Both regimens were repeated every 4 weeks.
  4. 04HumanNon-randomized trialSafety outcome

    In patients with refractory ovarian cancer, no dose reduction occurred in the leuprorelin arm.

    In plain wordsIn patients with refractory ovarian cancer, no dose reduction occurred with leuprorelin.

    Peptide
    Leuprolide
    Outcome
    Not applicableDose reduction
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    3.75 mg every 4 weeks · subcutaneous or intramuscularAs given in this study (human).

    Source sentences

    Summary
    Treatment delay was observed rarely and dose reduction was performed only in the treosulfan arm in 5% of 150 courses.
    2 context sentences
    Summary · context
    Patients with ovarian cancer progressing during platinum-paclitaxel containing first-line therapy or experiencing relapse within 6 months were eligible.
    Summary · context
    Treatment consisted of either treosulfan 7 g/m5 infused over 30 min or leuprorelin 3.75 mg injected subcutaneously or intramuscularly. Both regimens were repeated every 4 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.